UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

March 12, 2026

Date of Report (Date of earliest event reported)

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan 

(Address of principal executive offices)

886-6-3121716

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Item 8.01 Other Event

As previously disclosed, on July 18, 2025, Advanced Biomed Inc. (the “Company”) received a written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq” or the “Staff”) notifying the Company that the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days, or until January 14, 2026, to regain compliance with the Minimum Bid Price Requirement.

The Company did not regain compliance with the Minimum Bid Price Requirement by January 14, 2026. Accordingly, by letter dated January 16, 2026, the Staff notified the Company that its securities would be scheduled for delisting from Nasdaq and suspended at the opening of business on January 27, 2026, unless the Company requested an appeal of this determination before a Nasdaq Listing Qualifications Hearings Department (the “Panel”).

On January 21, 2026, the Company appealed the Staff’s delisting determination by submitting a hearing request to the Panel, which stayed the suspension of the Company’s securities and the filing of a Form 25-NSE pending the Panel’s decision. A hearing was held on February 17, 2026. The Company presented to the Panel a plan to regain compliance with the Minimum Bid Price Requirement, including the implementation of a reverse stock split approved by the Company’s stockholders on January 12, 2026.

On March 12, 2026, the Company received a written decision from the Panel stating that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2). The Panel determined that, following the Company’s reverse stock split completed on February 20, 2026, the Company had maintained a closing bid price of $1.00 or more per share, and therefore the Company is in compliance with the Minimum Bid Price Requirement. As a result, the Company’s common stock will remain listed on The Nasdaq Stock Market, subject to a one-year Panel monitor pursuant to Nasdaq Listing Rule 5815(d)(4)(A).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.